For example, Deaglio's group recently showed that extracellular NAMPT levels were elevated in 113 patients with BRAF-mutated metastatic melanoma compared to 50 with localized disease and to 38 healthy donors, showing a direct correlation with markers of tumor burden, such as LDH or aggressive disease (such as PD-L1). Here, NAMPT is linked to neoplasm.